Skip to main content
7573 results

29 Patients with MDA-5+ Dermatomyositis compliated by ILD were treated with high‐dose steroids, tacrolimus, and IV cyclophosphamide +/- Plasmapheres. 6 mos survival was better (89% and 33%, respectively, P < 0.0001) compared to 15 pts not treated https://t.co/utPiaQlUZF

Dr. John Cush @RheumNow  (  View Tweet)

Sep 20, 2019

The RheumNow Podcast is up – Should you Believe in Vitamin D or Rituximab? Watch it on RheumNow>> https://t.co/bX5u9KcKYz or listen to the podcast on iTunes or SoundCloud>> https://t.co/MxDcIyej3L

Dr. John Cush @RheumNow  (  View Tweet)

Sep 21, 2019
Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc

Dr. John Cush @RheumNow  (  View Tweet)

Sep 22, 2019
Altoona Arthritis Center and Dr. Alan Kivitz praised in the news for their unique blend of patient care and clinical trials research https://t.co/9kGLBhwzsn

Dr. John Cush @RheumNow  (  View Tweet)

Sep 23, 2019
Renal Review on treating asymptomatic hyperuricemia in CKD patients finds very few studies demonstrating renal protective effects w/ ULT w/ an abnormal uric acid. (this is without consideration of degree of CKD or hyperuricemia) https://t.co/nKo018lb6v

Dr. John Cush @RheumNow  (  View Tweet)

Sep 23, 2019
FDA issues warning against the use of higher doses of Imodium (loperamide) - has been associated with "serious heart problems and deaths with much higher than the recommended doses of loperamide". https://t.co/UxPn6F6BL0

Dr. John Cush @RheumNow  (  View Tweet)

Sep 23, 2019
Systemic sclerosis is associated with an increased cancer risk. A cohort of 1727 SSc pts showed an increased cancer SIR of 2.15 (CI 1.84‐2.49). Most common cancers were breast, melanoma, hematological & lung. CA risk higher w/ RNAP III Ab, CCB Rx & ILD https://t.co/q5iTRI91Ng

Dr. John Cush @RheumNow  (  View Tweet)

Sep 23, 2019
Question for Rheumatologists - How do you scoreboard your performance as a Rheumatologist?

Dr. John Cush @RheumNow  (  View Tweet)

Sep 24, 2019
JAMA study shows inconsistencies and inaccuracies in EMR documentation of ROS and PE findings compared to observer audible recorded observations - study of 9 ED Residents, 30 pt encounters each, total of 180 ED patients. https://t.co/PttGYvgCue

Dr. John Cush @RheumNow  (  View Tweet)

Sep 25, 2019
41 participants with RA and T2D were randomised to recv anakinra or a TNFi; RA dz activity decreased in both groups over 6 mos. Anakinra significantly improved A1C at 3 and 6 mos, but TNFi did not. https://t.co/UIBsRjMbKR

Dr. John Cush @RheumNow  (  View Tweet)

Sep 25, 2019

"People don't believe what you tell them. They rarely believe what you show them. They often believe what their friends tell them. They always believe what they tell themselves." - SETH GODIN

Dr. John Cush @RheumNow  (  View Tweet)

Sep 19, 2019

142 pts with ANCA-Associated Vasculitis were studied for lipid levels - Lipid levels increased during remission in newly diagnosed AAV and PR3+ AAV (not MPO or relapsing pts). Lipid levels correlated w/ ESR but not other inammatory markers. https://t.co/9UgUXv6BhI

Dr. John Cush @RheumNow  (  View Tweet)
Sep 20, 2019
Question for Rheumatologists - How do you scoreboard your performance as a Rheumatologist?

Dr. John Cush @RheumNow  (  View Tweet)

Sep 25, 2019
IL-2 inhibitor

Low Dose IL-2 Effective in Lupus

Sep 18, 2019

A double-blind, placebo-controlled clinical trial of low-dose IL-2 in patients with systemic lupus erythematosus (SLE) has shown that low-dose IL-2 induced was clinically effective while expandng regulatory T cells and NK cells, which may benefit immune homeostasis in SLE patients.

Read Article
Dr. Rob Speira & HSS investigators will lead a multicenter, phase II, 6 mos clinical trial of anti-GM-CSF (mavrilimumab) in patients with giant cell arteritis (GCA. There is still heavy reliance on steroids in GCA; tocilizumab was FDA approved in in 2017 https://t.co/zDWgSVuXec

Dr. John Cush @RheumNow  (  View Tweet)

Sep 27, 2019
×